Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Beads > Spike RBD > MBS-K034

SARS-CoV-2 Spike RBD (B.1.1.7) Coupled Magnetic Beads

The Magnetic Stand (Cat.No. MB-01 & Cat.No. MB-02) can be used in conjunction with Beads.

Order Now

ItemsSize (2mg)Size(5mg X 2)
Particle size2 μm2 μm
Physical appearancePowder mixturePowder mixture
Amount of Coupled Protein≈1194 pmol (33.8 μg) SARS-CoV-2 RBD protein/mg beads≈1194 pmol (33.8 μg) SARS-CoV-2 RBD protein/mg beads
Binding Capacity>300 pmol (33 μg) Human ACE2 ligand/mg beads>300 pmol (33 μg) Human ACE2 ligand/mg beads
FormulationPBS, pH7.4, with 10% TrehalosePBS, pH7.4, with 10% Trehalose
Reconstitution2 mL sterile deionized water (1 mg beads/mL)5 mL sterile deionized water (1 mg beads/mL)
  • Background
    The SARS-CoV-2 Spike RBD (B.1.1.7) Coupled Magnetic Beads is produced by coupling biotinylated SARS-CoV-2 spike RBD to streptavidin-conjugated magnetic beads. The spike RBD coupled to the beads contains the critical N501Y mutation identified in multiple circulating SARS-CoV-2 variants, e.g. the U.K. variant (known as B.1.1.7, 20B/501Y.V1 or VOC 202012/01), the South African variant (known as B.1.351 or 20C/501Y.V2) and the Brazilian variant (known as P.1). The pre-coupled beads are ready to use for capturing anti-SARS-CoV-2 antibody or ACE2 protein from your sample with high specificity.
  • Source
    SARS-CoV-2 Spike RBD (B.1.1.7) Protein is expressed from human 293 cells (HEK293). It contains AA Arg 319 - Lys 537(Accession # QHD43416.1 (N501Y)).
  • Application
    This product is intended for immunocapture, biopanning and flow cytometry. This product is produced non-sterile.
  • Reconstitution

    See Certificate of Analysis (CoA) for detailed instruction.

  • Storage
    Upon receipt, please store the Beads at -20°C. The shelf life is 1 year at -20 °C.Please avoid more than 3 freeze-thaw cycles once reconstitution, immediate use after reconstitution is highly recommended.
  • Assay Principles
    Antibody Purification: 1. Resuspend the lyophilized beads by adding the buffer of choice. 2. Add analyte to the suspension, mix and incubate to enable specific binding of the beads and the target protein. 3. Magnetize beads, remove supernatant, and wash unbound protein fractions to capture target protein-bound beads. 4. Wash, magnetize the beads and collect purified target protein for use in downstream applications.

    The magnetic beads technology makes use of the easy and efficient collection of beads in magnetic field to facilitate antibody purification in a simple workflow of “bind-wash-elute”. In contrast to common separation techniques, this method does not require columns or centrifugation, and is therefore ideal in high-throughput applications.

  • Formulation

    Please contact us for detailed information.

    Contact us for customized product form or formulation.

Typical Data
 Spike RBD TYPICAL DATA

Immobilized 33 μg RBD protein (Cat. No. SPD-C82E6) /1mg beads can bind ACE2 (Cat. No. AC2-H5257) with an EC50 of 1.337 μg/mL.

 Spike RBD TYPICAL DATA

Immobilized 56 μg SARS-CoV-2 Spike RBD (B.1.1.7)/1 mg beads can bind Anti-S1 Ab (Cat. No. S1N-M122) with an EC50 of 0.1069 μg/mL.

  • Clinical and Translational Updates

Comments (0)


ETA of in-stock products: 2 business days

Price(USD) : $800.00

Price(USD) : $2500.00

Promotion & Exhibitions



Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message